Titan Pharmaceuticals Inc
NASDAQ:TTNP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Titan Pharmaceuticals Inc
Pre-Tax Income
Titan Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
Pre-Tax Income
-$4.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-7%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$24.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
$9.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$7.5B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$21.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$25.7B
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
25%
|
|
Titan Pharmaceuticals Inc
Glance View
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
See Also
What is Titan Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-4.7m
USD
Based on the financial report for Dec 31, 2024, Titan Pharmaceuticals Inc's Pre-Tax Income amounts to -4.7m USD.
What is Titan Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-7%
Over the last year, the Pre-Tax Income growth was 15%. The average annual Pre-Tax Income growth rates for Titan Pharmaceuticals Inc have been 19% over the past three years , 9% over the past five years , and -7% over the past ten years .
